|
|
Commercial Insight: Antihypertensives - Two Years to Shape the Market?Published by: Datamonitor Published: Dec. 21, 2005 - 200 Pages Table of ContentsTABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 Objective of the analysis 3 Datamonitor insight into the hypertension market 4 CHAPTER 2 MARKET DEFINITION AND OVERVIEW 11 Market definition and overview for this report 11 Hypertension 12 Disease overview 12 Epidemiology 13 Treatment options; the antihypertensive drug classes 15 Drugs that inhibit the renin-angiotensin system (RAS) 16 Drugs that do not inhibit the renin-angiotensin system (RAS) 31 Other classes of antihypertensive drugs 33 CHAPTER 3 COUNTRY MARKET ASSESSMENTS 35 Current and future opportunities and threats in the antihypertensives market 35 The global market: overview, opportunities and threats 35 Overview 35 National markets 41 The global movers and shakers 43 Global opportunities 44 Global threats 54 US market: overview, opportunities and threats 54 Overview 54 US market issues 56 Japan: overview, opportunities and threats 67 Overview 67 Japanese market issues 69 European Union: overview, opportunities and threats 79 Overview 79 EU market issues 82 CHAPTER 4 FORECAST ANALYSIS 88 Assumptions and events 88 Ongoing trends 88 Increasing market size 88 Increasing use of fixed-dose combinations 88 Trial results 88 New product launches 91 S-amlodipine 91 SPP100 (aliskiren) 92 Caduet 92 Patent issues 93 ARB patent expiries 94 CCB patent expiries 95 Beta-blocker patent expiries 96 ACE inhibitor patent expiries 96 Other patent expiries 96 Additional indications 97 Irbesartan gains congestive heart failure indication 98 Valsartan gains additional diabetes indication 99 Methodology 99 Forecasts 99 CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES 100 Introduction 100 Case study 1 100 Novartis and the “renin revolution” 100 Case study 2 113 Clinical trial data and the potential to change prescribing habits 113 Case study 3 122 EU healthcare reforms: a tale of two countries 122 APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS 134 Global hypertension market data 134 Major brand facts 134 C7 BBs 134 C8 CCBs 136 C9 ACEIs 138 C9 ARBs 140 Anatomical Therapeutic Chemical (ATC) classification 143 APPENDIX B 145 Bibliography 145 Hypertension management guidelines 145 JNC 7 145 ESH/ESC 145 WHO/ISH 145 BHS-IV 145 References 146 Report methodology 148 General 148 Japan sales data 148 Key opinion leaders 148 About Datamonitor 149 About Datamonitor Healthcare 149 About the Cardiovascular Disease analysis team 150 Disclaimer 151 Glossary 152 APPENDIX C - MARKET FORECAST DATA 153 US forecasts 153 Japan forecasts 158 France forecasts 162 Germany forecasts 167 Italy forecasts 172 Spain forecasts 177 UK forecasts 182 M5EU forecasts 187 Global forecasts 194 AbstractIntroductionDatamonitor expects the antihypertensive market to exceed $50bn by 2014 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to be savvy regarding marketing and pricing structures for their products, as only the most cunning and aggressive companies look set to survive. Scope Event-driven sales forecasts, for the period 2005-14, for the US, Japan, France, Germany, Italy, Spain and the UK, along with a global overview Discussion of individual products in four main classes; beta blockers (BBs), CCBs, ACE inhibitors and the ARBs Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches Commercial impact case studies on R&D innovation, clinical trial data and European healthcare reform Highlights The ARBs are now the most prescribed class of antihypertensives, as aggressive marketing and premium-pricing enables manufacturers to deliver strong growth in a highly genericized market. Post-2009, however, the value of the ARB class is set to flatten on the back of generic erosion and indication expansion for the ARBs as a class. In order for companies to achieve and maintain growth in this sector, companies need to be savvy regarding the impact of healthcare reform across the globe, particularly in Europe, with marketers who are charged with selling drugs across the EU needing to challenge the attitude that Europe is one, uniform, market like the US and Japan. Novartis' SPP100 (aliskiren) looks set to become the first innovative treatment for hypertension in over a decade. However, due to concerns regarding premium-pricing and similar efficacy compared to the ARBs, market penetration is expected to be slow in the short-term until strong cardiovascular outcome data for the class becomes available. Reasons to Purchase Access independent, event-driven forecasts for key antihypertensive products and classes across the seven major markets Assess the potential impact of clinical trial results, EU healthcare reform and new product launches on the antihypertensive market Gain insight into the antihypertensive market via up-to-date thought-leader opinions and gold-standard IMS Health sales data Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||